# Study of EOC317 in Chinese Patients With Advanced Solid Tumors

> **NCT03583125** · PHASE1 · UNKNOWN · sponsor: **Taizhou EOC Pharma Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** EOC317

## Key facts

- **NCT ID:** NCT03583125
- **Lead sponsor:** Taizhou EOC Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-29
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-11-29
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583125, "Study of EOC317 in Chinese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03583125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*